These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29798767)

  • 21. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.
    Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G
    BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial.
    Gomez-Lara J; Brugaletta S; Ortega-Paz L; Vandeloo B; Moscarella E; Salas M; Romaguera R; Roura G; Ferreiro JL; Teruel L; Gracida M; Windecker S; Serruys PW; Gomez-Hospital JA; Sabaté M; Cequier A
    JACC Cardiovasc Interv; 2018 Aug; 11(16):1559-1571. PubMed ID: 29805111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent.
    Mattke S; Hanson M; Dallmann AC; Bentele M
    Cardiovasc Revasc Med; 2019 Sep; 20(9):752-757. PubMed ID: 30638888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
    Kereiakes DJ; Ellis SG; Kimura T; Abizaid A; Zhao W; Veldhof S; Vu MT; Zhang Z; Onuma Y; Chevalier B; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2017 Jan; 10(1):42-49. PubMed ID: 28017311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial.
    Costa JR; Abizaid A; Whitbourn R; Serruys PW; Jepson N; Steinwender C; Stuteville M; Ediebah D; Sudhir K; Bartorelli AL;
    Catheter Cardiovasc Interv; 2019 Jan; 93(1):E1-E7. PubMed ID: 30286520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Very late stent thrombosis in everolimus-eluting stent with predisposing mechanical factors: Differential features.
    Jaguszewski MJ; Cortes C; Daucher H; Schincariol M; Halejcio M; Besuch P; Gutiérrez-Chico JL
    Cardiol J; 2017; 24(4):345-349. PubMed ID: 28831778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
    Vesga B; Hernandez H; Moncada M; Gasior P; Higuera S; Dager A; Arana C; Delgado JA; Généreux P; Maehara A; Granada JF
    Coron Artery Dis; 2017 Mar; 28(2):126-134. PubMed ID: 27879518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Bioresorbable Vascular Scaffold System.
    Steinvil A; Rogers T; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1757-64. PubMed ID: 27609249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial.
    Xu B; Zhang YJ; Sun ZW; Qiao SB; Chen SL; Zhang RY; Pan DR; Pang S; Zhang Q; Xu L; Yang YJ; Leon MB; Gao RL
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1489-96. PubMed ID: 26208685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An observational study of clinical outcomes of everolimus-eluting bioresorbable scaffolds comparing the procedural use of optical coherence tomography against angiography alone.
    Hamshere S; Byrne A; Guttmann O; Rees P; Bourantas C; Weerakody R; Wragg A; Knight C; Mathur A; Jones DA
    Coron Artery Dis; 2018 Sep; 29(6):482-488. PubMed ID: 29642228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early healing assessment with optical coherence tomography of everolimus-eluting stents with bioabsorbable polymer (synergy™) at 3 and 6 months after implantation.
    de la Torre Hernández JM; Tejedor P; Camarero TG; Duran JM; Lee DH; Monedero J; Laso FS; Calderón MA; Veiga G; Zueco J
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):E67-73. PubMed ID: 26526783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice).
    Smits PC; Vlachojannis GJ; McFadden EP; Royaards KJ; Wassing J; Joesoef KS; van Mieghem C; van de Ent M
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1157-1165. PubMed ID: 26210806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.